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ABSTRACT
A spectrophotometric method for the determination of low 
levels of gold(III) with di-2-pyrldylketoxime was developed.
A stable 2j1 water-soluble complex is formed having an 
absorption maximum at ^33 nm and a molar absorptivity of
Ij,
1.89 x 10 . The Beer-Lambert law is obeyed up to 12 ppm. The 
method was applied to the determination of gold in plasma and 
urine. The method is simple, reproducible and relatively 
rapid.
li
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CHAPTER I
INTRODUCTION
Gold and its derivatives have been used in medicine 
throughout written history to treat every conceivable dis­
order. The beginning of a rational chemotherapy with gold 
came with Koch's demonstration (1) in 1890 that potassium 
auricyanide inhibited the growth of the tubercle bacillus in 
vitro at a concentration of 1 in 2 million. White (2) in 
189^ showed that sodium aurichloride had some antibacterial 
effect in tuberculosis but was toxic.
In 1913» several reports appeared to the effect that
«
simple gold compounds such as potassium auricyanide showed 
therapeutic activity in cases of tuberculosis and syphilis. 
This was sufficient to encourage attempts to develop better 
tolerated derivatives such as that of Spiess and Peldt (3). 
They introduced what was considered to be a less toxic com­
plex of aurous cyanide, 'Aurocantan* (cantharidylethylenedi- 
amine aurocyanide), but this compound caused necrosis after 
repeated subcutaneous administration and its use was limited.
The outstanding feature of the chemistry of gold is the 
'nobility' of the element, that is, the difficulty with which 
it can be made to participate in chemical reactions and form 
firm chemical bonds with other elements. Furthermore such 
compounds are relatively unstable and often revert under
1
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mild conditions to the elemental form.
Both Au(I) and Au(III) show an extremely marked tenden­
cy to form complexes and in so-called gold salts of ionic 
character in aqueous solution, the ions always involve gold 
complexed with other elements.
A certain lack of understanding of the precise nature 
of complex gold derivatives has led to some confusion in 
past work on the mode of action of these substances and some 
misconceptions of the structural formulae of those compounds 
which have been put to clinical use. Both Au(I) and Au(III) 
compounds exist among such substances. It is worth noting 
that the coordination number in Au(I) compounds is almost 
always two and that there is a strong affinity for sulfur,
little for nitrogen and carbon and none for oxygen; while
the more stable and numerous Au(III) compounds are always
four-coordinate and there is a marked affinity for oxygen
and halogen, some affinity for nitrogen and none for sulfur. 
These considerations lie behind the development of particu­
lar water-soluble derivatives of gold for chemotherapeutic 
use, through the selection of suitably ionized complexing 
systems.
The frequency with which gold-sulfur complexes have
appeared among chemotherapeutic gold derivatives supported 
the idea that their activity owed more to the sulfur content 
than the gold. This was successfully disposed of by Preston, 
Block and Preyberg (*J-).
Spiess and Peldt (5) developed 'Krysolgan* (2-auro-thio-
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4-aminobenzoic acid) in which the gold(I) was linked to an 
organic molecule through a firm sulfur bond. Other workers 
supported Feldt*s claim that 'Krysolgan' was as active as 
sodium auricyanide against Mycobacterium tuberculosis but 
could not confirm his view that it was much less toxic.
The next decade saw the introduction of a number of 
other gold-sulfur complexes as tuberculostats and antisyph­
ilitic agents. Feldt, undaunted by the severe toxic effects 
of these gold compounds, pursued his study of aromatic auro- 
thio derivatives and there appeared successively 'from the 
Farbwerke Hoechst laboratories the water-soluble products 
*Solganal* (3-aurothio-*t— sulfophenylaminomethanesulfonate), 
introduced to clinical practice about 192?, and the hetero­
cyclic aurothio compound 'Triphal* (sodium 2-auro^thiobenz- 
imidazole-4-carboxylate). These compounds were administered 
intravenously.
In the meantime, the compound sodium aurothiosulfate 
which Feldt had shown in 1913 to have antibacterial activity 
had been studied clinically in the treatment of tuberculosis 
by Mollgaard (6). It was introduced clinically under the 
trade name 'Sanochrysin'; it too was injected intravenously. 
This inorganic gold complex outlived the organic compounds 
previously mentioned and its use for the treatment of tuber­
culosis lingered on into the period when modern antitubercu­
losis agents had become available.
Further gold-sulfur organic complexes were developed in 
the next decade, including 'Lopion' (sodium 3- [l-(3-allyl-5“
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4auropseudothioureido)J benzoate) by the research workers of 
the German company Bayer A.G.; and the carbohydrate complex, 
aurothloglucose by the Hoechst group.
The next major development in the chemotherapy of gold 
lies to the credit of French workers. Martenstein (7) had 
introduced the use of gold compounds in the treatment of 
lupus erythematosus on the basis that this disorder was a 
manifestation of tuberculosis. However erroneous this idea 
may have been, the treatment with gold salts of cases resist­
ant to preferred remedies continues today. It was because 
of a similar association imagined between tuberculosis and 
rheumatoid arthritis that another French clinician Forestier 
(8,9) began to treat sufferers from this hitherto completely 
intractable disease with a new gold compound 'Allochrysine* 
(sodium 3-au*‘othio-2-propanol-l-sulfonate) of French origin 
and to achieve a striking measure of success.
'Allochrysine' was introduced by Lumiere and Perrin 
(10) in 1927. It was followed in 1932 by the development of 
'Myochrysine' (sodium aurothiomalate) in the Rhone-Poulenc 
research laboratories.
Many other European investigators confirmed Forestier"s 
original findings but the level of toxic reactions continued 
to be a deterrent to the more intensive use of the available 
products. This particularly delayed the exploitation of 
gold therapy in the United States. Various attempts were 
made during the 1930's to minimize toxicity by the intro­
duction of insoluble forms of gold compounds,normally in
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oily suspension.
The American contribution to new gold derivatives has 
been limited to 'Lauron' (oC-aurothioacetanilide) but Amer­
ican workers, particularly Freyberg, Block and their coll­
eagues (11-16), working about the period of the 1939-45 
war, have made major contributions to the understanding of 
the distribution and fate of the more important gold comp­
ounds in animals and man and have made various attempts to 
elucidate their mode of action.
Gold compounds used in medicine have a variety of bio­
logical aspects, among them antibacterial properties (17-31) 
and other pharmacological effects (16, 32-43).
When water-soluble derivatives are injected intramuscu­
larly, the plasma levels in man reach a maximum within an 
hour and are then of the same order as the peak level after 
intravenous injection! these compounds are obviously very 
rapidly absorbed. The comparatively high plasma levels are 
maintained for at least 24 hours. Major amounts of both 
insoluble and soluble gold compounds are taken up by the kid­
neys, spleen and liver, the soluble salts being extensively 
protein-bound. Small amounts of gold may be found in almost 
every tissue, including the central nervous system and foet­
al tissues in pregnant animals. Synovial fluid levels tend 
to run parallel with plasma levels and do not exceed them - 
there is no indication of selective concentration in these 
fluids.
The soluble compounds are generally accepted as being
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more potent In clinical use, but at the same time more like­
ly to produce systemic toxic effects. This has given rise to 
attempts to mitigate the toxic symptoms, without Impairing 
the therapeutic effects, by providing a delayed release of 
material from a depot formed at the site of injection.
Many of the conclusions of earlier work have been sub­
stantiated by modern studies with radioactive gold (^®Au) 
either as the colloidal metal or in combined form. Lawrence 
(44) gave intramuscular injections of sodium aurothiomalate 
labelled with radioactive gold. High levels of radioactivity 
were distributed throughout the body within 15 minutes. It 
was found that painful joints in an arthritic subject contain­
ed up to 2.5 times as much gold as symptomless joints; and 
that there was a marked concentration in fibrin clots from 
joints and in articular cartilage. Lawrence was unable to 
relate the activity of the disease to plasma levels or ex­
cretion rates of gold. Kleinsorge et al. (45) have shown, 
by the use of tagged compounds given orally, that absorption 
from the digestive tract occurs readily but plasma levels 
are never high and excretion is comparitively rapid.
All gold compounds are excreted over a prolonged period, 
reflecting the firm binding of much of the administered dose 
in the reticulo-endothelial cells. Water-soluble compounds 
are excreted in quantity in the urine in the 24 hours after 
injection, and the majority of a dose is eliminated by the 
eighth day; detectable amounts may continue to be present 
for as long as 6 to 12 months (15)•
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The detailed metabolism of gold compounds has not been 
worked out (46). Earlier workers thought that sodium auro- 
thiosulfate was deposited in various tissues as metallic gold 
or auric sulfide. In general, investigators have been con­
tent to assay gold as the metal and to ignore the precise 
complex form in which it might be present. Kleinsorge et al. 
(4-5) however, observed that radioactively labelled materials 
were excreted unchanged in the urine.
Since about I960, gold salts have enjoyed a marked re­
surgence in the treatment of rheumatoid arthritis. Today 
about 80-90 % of the nation's rheumatologists use gold salts 
to treat patients suffering from chronic, progressive rheum­
atoid arthritis.
Among the chief motivations for the increasing use of 
gold salts since i960 has been the growing awareness of the 
severe side effects of the corticosteroids when used over 
long periods of time and the mounting apprehension about the 
widespread application of the drugs. Another has been the 
realization that gold salts can be used effectively in small­
er doses and with less frequency and thus with fewer harmful 
side reactions. Also, scientists now realize that, despite 
the early euphoric hopes, the steroids do not cure rheumat­
oid arthritis, any more than do gold salts and aspirin.
After several months of use, gold salts are notably 
effective in many patients in reducing inflammation and 
swelling in arthritic joints. It is believed that gold salts, 
unlike most arthritic drugs, markedly slow down the dlsint-
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egration of joint cartilage and bone that is characteristic 
of rheumatoid arthritis. This destructive process is not 
completely halted, however.
How gold salts bring about their beneficial effects has 
been the subject of unrelenting debate. Persellin and Ziff 
(If?) reported that gold salts are selectively concentrated 
in lysosomes. There and elsewhere, they act as lysosomal 
enzyme inhibitors. Gerber (48) indicated that gold compounds 
block the interchange of sulfhydryl and disulfide groups on 
gamma globulin and other proteins. Since sulfhydryl-disulf- 
lde interchange often occurs when proteins are damaged, a 
compound that prevents this interchange may also prevent the 
breakdown of proteins. Damaged proteins can act as antigens. 
These antigens can, in turn, cause the production of anti­
bodies that can subsequently form antigen-antibody complexes. 
These complexes, if engulfed by white blood cells, can lead 
to the release of inflammation-producing lysosomal enzymes. 
This series of reactions may be inhibited by the ability of 
gold compounds to interfere with the formation of damaged, 
antigenic proteins.
Numerous methods have been employed for the determinat­
ion of gold in biological materials, among them neutron act­
ivation (49-55), emission speetrography (56,57), polarography 
(58-61) and colorimetry (62,63). Most colorimetric methods 
involve (i) destruction and removal of interfering substan­
ces, (ii) formation of gold(III) chloride with aqua regia 
and (iii) oxidation of various substrates by gold(III) chlor-
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ide to intensely colored products. The solutions of the 
colored products obey the Beer-Lambert law and serve as the 
basis for quantitation. Of these, the colorimetric o-dian- 
isidine method (62) has been most extensively used. This 
method has been criticized by Fraser et al. (6^ ) as being 
non-reproducible and inaccurate. Inasmuch as the procedure 
of digestion by sulfuric acid and hydrogen peroxide is rel­
atively tedious and time consuming, it was proposed that the 
use of chloric acid as digestant would shorten the time re­
quired for digestion.
In the present work it was felt that a more specific 
color reaction was desirable, having as its basis the form­
ation of a stable water-soluble gold(III) complex requiring 
no extraction into an organic phase. Di-2-pyridylketoxime 
(DPK),(I), which has been reported as a new reagent for the 
spectrophotometric determination of gold (65), palladium 
(66), cobalt (67) and iron (68), is also suitable for the 
determination of gold in aqueous solution. Due to the re­
newed interest in gold therapy for the treatment of rheuma­
toid arthritis it was felt that a simple and rapid procedure 
was needed for the determination of trace amounts of gold 
(III) in plasma and urine.
Di-2-pyridylketoxime has the advantages that its ethan- 
olic solution is stable indefinitely, and that its symmetry 
precludes s.yn- and anti-isomers. Furthermore, the ketone is 
commercially available and preparation of the oxime is 
simple and rapid (69).
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Di-2-pyrid.ylketoxime
Two possible structures for the complex arei
(1)
N- ~ ~ ^  N 
/
N —  Au/2
1+
(2)
N
N. Au/2 
0^
1+
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CHAPTER II
EXPERIMENTAL
A. MATERIALS AND METHODS 
Apparatus
Spectral studies and light absorbance measurements were 
made with a Beckman DB spectrophotometer equipped with a 
Sargent Model SRL recorder, and a Beckman DUE spectrophoto­
meter equipped with a Gilford Model 2000 Multiple Sample 
Absorbance Recorder and a Haake thermostatted circulating 
water pump. All absorption measurements were obtained at 
25 - 0.5°C with matched silica cells of 1 cm path length.
The pH studies were made with a Beckman Model G pH meter 
equipped with standard glass-calomel electrodes.
Reagents
Preparation of dl-2-pyrldylketoxime
The parent ketone was purchased (Aldrich Chemical Co.)
and converted directly (69) with hydroxylamine hydrochloride
to the oxime. Crystallization from water gave the oxime as
fine colorless needles, mp 1*K3-1^»5°c (uncorrected).
Analysis* calculated for C H ON 1 66.32% C, k.55% H, 21.09
11 y j
% Nj found* 65.78% C, *4-. 53$ H, 20.96$ N. Analyses were 
performed by Schwarzkopf Microanalytical Laboratory, 56-19
11
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37th Avenue, Woodside, New York 11377*
Dl-2-pyridylketoxime solution
The oxime was used as a 1% (w/v) solution in 95$ 
ethanol. The solution is colorless and stable indefinitely.
Standard gold solution
The standard gold solution (2 mg/ml) was prepared from 
Fisher ACS reagent, HAuCl^, 31^0 and standardized gravimetri- 
cally with hydroquinone according to the method of Beamish, 
Russell and Seath (70).
Chloric acid (71)
Chloric acid was prepared by weighing 500 gm of potas­
sium chlorate into a 3-1 beaker, adding 900 ml of distilled 
water and heating on a hot plate until dissolved. The beaker 
was removed from the hot plate and 375 ml of 72$ perchloric 
acid were added with constant stirring. The covered beaker 
was kept in a refrigerator for 24 hours to effect complete 
precipitation of the potassium perchlorate. The solution 
was filtered on a Buchner funnel with suction through a 
Whatman 5^1 paper. The filtrate contains approximately 28$ 
chloric acid. The solution was stored in a refrigerator at 
3°C.
Aqua regia
Three parts of concentrated reagent HC1 were added to 1 
part of concentrated reagent HNO^. This solution was pre­
pared fresh daily.
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Potassium fluoride solution
A sufficient quantity of reagent-grade potassium 
fluoride was dissolved in distilled water to give a final 
concentration of 20 mg F**/ml and was stored in a polyethyl­
ene bottle.
Potassium hydrogen phthalate - HG1 buffer
A Clark and Lubs buffer of pH 3*0 was prepared in the 
usual manner.
Other reagents
All other reagents were of reagent-grade.
Procedure
Determination in pure solutions
An aliquot of solution containing approximately 30-250 
jig of gold was placed in a 25-ml volumetric flask. To this 
were added 5 ml of potassium hydrogen phthalate - HC1 buffer 
of pH 3.0. Two milliliters of DPK solution were added and 
the flask was filled to the mark with distilled water. The 
yellow color was allowed to develop for at least 10 minutes 
and the absorbance was measured at 433 *im. A blank was pre­
pared in the same manner without the addition of gold.
Determination in plasma
One milliliter of plasma was pipetted into a 180-ml 
electrolytic beaker which contained a glass bead. To the 
beaker were then added 10 ml of chloric acid. The beaker
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was covered with a Speedyvap watch glass and placed on a hot 
plate. Digestion was allowed to proceed to complete dryness 
and the crystalline residue was heated until the dense fumes 
of perchloric acid disappeared. To the cooled beaker were 
added 3 ml of aqua regia. The beaker was covered again with 
a watch glass and placed on a hot plate and allowed to evap­
orate to near dryness. At this point 4-5 drops of aqua regia 
were added and the walls of the beaker and the watch glass 
were washed with 12 N HC1. It is important not to dry the 
contents of the beaker because the gold is easily reduced and 
low results will be obtained. As the evaporation proceeds 
the solution should be replenished with 12 N HC1 to ensure 
complete removal of nitrosyl chloride and other lower oxides 
of nitrogen. After 2 or 3 such treatments with 12 N HC1 the 
beaker was removed from the hot plate, cooled and 5 ml of pH 
3.0 buffer and 0.5 ml of KF solution were added. The pH was 
adjusted to 3.0 by the addition of solid NaHCO^. Two milli­
liters of DPK solution were added and the contents were 
transferred to a 25-ml volumetric flask and filled to the 
mark with distilled water. Within 10 minutes of the addition 
of DPK the absorbance was measured at 433«m* A gold-free 
plasma blank was not required since a blank consisting only 
of buffer and DPK gave the same absorbance reading as a plas­
ma blank.
Determination in urine
Ten milliliters of urine were pipetted into a 180-ml 
electrolytic beaker which contained a glass bead. Twenty-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
15
five milliliters of chloric acid were added and the digestion 
was carried out as: outlined above for plasma except that 
after filling the flask to the mark, the colored solution 
was placed in a centrifuge tube and centrifuged for 1 minute 
to remove the residual salts. Within 8 minutes of the add­
ition of DPK the absorbance was measured at 433 nm. A gold- 
free urine blank was also carried through the determination.
Standards
Gold standards were prepared by appropriate dilution of 
the standard gold solution. For the determination of gold 
in plasma and urine the standards were digested and treated 
in the same manner as the samples as described above. In 
all cases the standards were read against a blank consisting 
of buffer and DPK.
Computer Programs
A least mean squares computer program (APPENDIX I) 
written in FORTRAN IV language and run on an IBM 360/40 
computer was used to find the equations of the lines of best 
fit for the continuous variation and molar ratio studies.
A computer program (APPENDIX II) written in FORTRAN IV 
language and run on an IBM 360/40 computer was used to calc­
ulate the mean, standard deviation and per cent relative 
standard deviation for the reproducibility study and the 
analyses in plasma and urine.
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B. RESULTS
Studies with HAuCl^,3HgO
Spectral characteristics
The absorption spectra of the gold(III) - di-2-pyridyl- 
ketoxime complex were determined at various pH values between 
0.4 and 6.5 in dilute sodium hydroxide or hydrochloric acid
media. The complex exhibited an absorption maximum at 433
nm and at this wavelength there was negligible absorption 
due to the reagent (FIGURE 1). The Beer-Lambert law was 
obeyed up to 12 ppm of gold. The optimum concentration 
range evaluated by Ringbom's method (72,73) was 2.4 to 7.0 
ppm (TABLE I). The molar absorptivity at 433 nm was I.89 x 
10 and the Sandell sensitivity (74) was 0.010 jig cm” .
Effect of pH
The effect of pH was studied by developing the complex 
for 30 minutes at room temperature and recording the absorb­
ance at 433 nm. The results are summarized in TABLE II.
The optimum pH range is 2.5-4.0.
Development of the complex
In the optimum pH range complex formation was maximal 
after 10 minutes employing 2 ml of DPK solution. The absorb­
ance of the complex was constant for 48 hours but decreased 
by approximately after 6 days.
Effect of reagent and temperature
A large excess of the DPK solution was used. There was
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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no significant change in absorbance whether 0.1 ml or 10 ml 
of the reagent solution were used. The only significant 
change was the time required to reach the maximum absorbance 
reading* 60 minutes and 8 minutes for 0.1 ml and 10 ml 
respectively (FIGURE 2).
Variation in temperature between 20 and 37° C did not 
significantly affect the absorbance readings (i.e. < 2%).
Composition and stability of the complex
Continuous variation and molar ratio studies indicated 
that the composition of the complex was 2»1 reagentjgold 
(FIGURE 3).
The dissociation constant of the complex (75) may be 
written as K =c*c(nc*c )n/c(l -oO where n = 2, c is the molar- . 
ity of the solution of the complex and ©£ is the degree of
Ag)/A^. The values of°c 
and c are obtained directly from FIGURE 3(B). A^ is the 
maximum absorbance obtained from the horizontal portion of 
tha curve and Ag is the absorbance at the stoichiometric 
molar ratio of reagent to gold in the complex. The experim- 
ental value of K was 1.4 x 10 . Reliable values of K are
generally obtained when Ag/AM is between 0.7 and 0.9 (76)5 
in this investigation the value was 0.86.
Reproducibility of the method
The reproducibility of the method was studied by analy­
zing (10 times) solutions containing known amounts of gold.
The results are summarized in TABLE III.
dissociation defined by cC - (A^
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Effect of diverse Ions
To study the effect of interferences, various foreign 
ions were added to 112 jig of gold and the determination per­
formed; a maximum error of 2% was considered tolerable. The 
results are summarized in TABLE IV. One mg of Fe(III) was 
masked with 10 mg of F~.
Preliminary Studies
Once the optimum conditions for the determination had 
been established it was decided to pursue the determination 
of gold in plasma. One milliliter of plasma and an aliquot 
of the standard gold solution were placed in an electrolytic 
beaker, chloric acid was added and the sample was digested 
to incipient dryness. The solution was neutralized with 1 N 
NaOH using phenolphthalein as indicator and the gold then 
converted to gold(III) chloride with 0.3 ml of aqua regia. 
Five ml of buffer and 2 ml of DPK solution were added and 
the color was developed. The results were not reproducible 
and the color was very unstable.
It was found that the buffer would not control the pH;
so after digestion and aqua regia treatment, the pH was adj­
usted to 3*0 with NaOH using a pH meter. Again the results
were not reproducible and the color was unstable.
The next series of experiments dealt with an attempt to 
improve the color stability by removing as much of the excess 
chloric acid as possible by heating to dryness on a hot plate 
until the dense fumes disappeared. The color stability im-
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proved but the results were still not reproducible.
It was thought that perhaps the NaOH used in adjusting 
the pH might be causing the difficulty due to the presence 
of localized regions of high pH. To investigate this, an 
aliquot of gold was taken and 1 ml of concentrated HC1 was 
added to simulate the highly acidic condition after aqua 
regia treatment. The pH was then adjusted with NaOH, DPK 
was added and the color developed. Low results were obtain- 
ed.
The above experiment was repeated except that solid 
NaHCO^ wa.s used to adjust the pH instead of NaOH. Good 
results were obtained. It was then decided to repeat the 
above experiment using a plasma sample containing gold. Low 
results were again obtained.
In the final stages of the aqua regia treatment, conc­
entrated HC1 is added to remove excess HNO^ and lower oxides 
of nitrogen which would reduce Au(III). At the same time, 
it is important that the solution in the beaker does not go 
dry since reduction of Au(III) will result. Up to this point 
in the investigation, the watch glass and walls of the beaker 
were always washed with distilled water. It was felt that 
a high chloride ion concentration might be needed to main­
tain the stability of the oxidized Au(IIl) - i.e. to prevent 
hydrolysis. With this in mind any washing or replenishing 
was done with concentrated HC1 and good recovery resulted.
The next step was to carry out replicate analyses at 
various levels of gold. At the 60 pg level, the color in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
20
the standards did not develop fully. At this point it was 
felt that the disodium (ethylenedinitrilo) tetraacetic acid 
(di-Na EDTA) may he interfering with the color development. 
The purpose of adding the di-Na EDTA was to mask the copper 
present in plasma (normally about 2 jxq/ml). To determine 
whether di-Na EDTA was interfering with color development, 
an aliquot of standard gold solution was taken and to it was 
added 0,2 ml of 0.1 M di-Na EDTA as had been done with the 
plasma samples and gold standards; buffer and DPK were added 
as usual. It was found that at both the 60 and 112 ^ tg levels 
of gold, color development was incomplete.
Another study was undertaken to find the tolerance 
limit for Cu(II) employing no EDTA as a masking agent. It 
was found that 10 jig ‘of Cu(II) could be tolerated (TABLE V) , 
hence eliminating the need for any EDTA.
Gold Determination in Plasma and Urine
The results obtained by the addition of known quantities 
of gold to plasma and urine are summarized in TABLE VI, and 
the number of samples and their distribution are indicated.
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TABLE I
DATA FOR RINGBOM PLOT
(jig Au/25 ml)
log [Au] Absorbance Absorptancy 
(1 - T)
30 1.477 0.120 0.241
60 1.778 0.239 0.423
115 2.061 0.448 0.642
170 2.230 0.661 0.782
250 2.398 0.963 0.891
300 2.477 1.161 0.931
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TABLE II
EFFECT OF pH ON ABSORBANCE
pH Absorbance
0.41 0.087
0.88 0.298
l.?8 0.347
2.08 0.343
3.10 0.330
3.66 0.330
5.37 0.311
5.85 0.180
6.06 . 0.130
6.34 0.094
6.51 0.055
(433 nm, 89 jig gold/25 ml)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
25
FIGURE 2 
EFFECT OF REAGENT CONCENTRATION 
Legend
Five ml of buffer solution and 11^ ^ tg of Au/25 ml were
used in all the studies.
(1) 5 ml DPK solution
(2) 2 ml DPK solution
(3) 10 ml DPK solution
W 1 ml DPK solution
(5) 0.5 ml DPK solution
(6) 0.1 ml DPK solution
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FIGURE 3
CONTINUOUS VARIATION AND MOLAR RATIO STUDIES
Legend
(A) Continuous variation study
Total concentration of Au and DPK, 1.0 x 10~^ M.
(B) Molar ratio study
Au, *K0 x 10“5 M with varying concentrations of DPK.
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TABLE III 
REPRODUCIBILITY DATA
Gold taken
4c
Absorbance/ Standarddeviation
Relative
standard
deviation
(ps/25 ml) (Absorbance
units)
CO
30 0.120 ±0.001 0.61
6° 0.239 ±0.000 0.18
115 0.448 ±0.002 0.46
170 0.661 ±0.002 0.2 6
250 0.963 ±0.001 0.14
300 1.161 ±0,001 0.11
* Each value is an average of 10 individual analyses.
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TABLE IV 
EFFECT OF DIVERSE IONS
Diverse ion
Tolerable amount 
of diverse ion 
(mg)
Na+ (Na2S0^) 33
K+ (KC1) 53a
Ca2+(CaCl2) .5
Mg2+[Mg(N03)2.6H2o] 5
Zn2+(ZnS0^.7H20) 5
cu2+[c u (no3)2.3H2o] 15*
Fe3+(FeCl3) 1°
C1"(KC1) 48a
F"(KF) 10
SO^2" (NagSO^) 68
po^3~(k h 2po4) 56
phthalate(KHCgH^O^) in buffer
a Amount added in addition to that present in buffer 
b Amount shown is in jig 
c Masked with 10 mg F“
I
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TABLE V
EFFECT OF COPPER(II)
Jig Cu(II) 
added
jag Au/25 ml
added found
% difference
0 60.0 60.0 0.0
10 60.0 61.5 +2. 6
20 60.0 62.6 +4.3
50 60.0 6k. 6 +7.7
100 60.0 67.2 +12.0
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RECOVERY OF KNOWN
TABLE VI 
AMOUNTS OF GOLD ADDED TO PLASMA AND URINE
Material
used
Volume Au
added
Recovery Standard
deviation
No. of 
deter­
minations
(ml) (pg) (%) (%)
Plasma 1.0 60 100.5 ±2.5 7
112 100.5 ±2.9 13
1?0 99.0 ±2.1 6
Urine 10.0 60 101.8 ±2.7 5
170 98.0 2
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CHAPTER III
DISCUSSION
The purpose of this investigation was to develop a 
method for the determination of gold in plasma and urine.
First, a study was undertaken with pure chloroauric 
acid (HAuCl^.3H20) to explore the possibilities of using 
DPK as a color reagent for gold(III),
Various analytical parameters were studied. The gold
(III) - DPK complex exhibited an absorption maximum at 433
nm and at this wavelength there was negligible absorption
due to DPK. The molar absorptivity at 433 nm was 1.89 x 10^
*
-2and the Sandell sensitivity was 0.010 jig cm . The Beer- 
Lambert law was obeyed up to 12 ppm (300 jig gold/25 ml) of 
gold. The optimum concentration range evaluated by Ringbom's 
method was 2.4-7.0 ppm (60-175 Jig gold/25 ml). The complex 
formed between pH 0.^ and 6.5* The optimum pH range is 2.5- 
4.0.
In this optimum pH range absorbance was maximal after 
10 minutes when 2 ml of DPK solution were employed. The 
absorbance was constant for 48 hours but decreased by approx­
imately 5% after 6 days.
There was no significant change in absorbance whether
0.1 or 10 ml of the reagent solution were used. Two ml of 
DPK solution were found to be optimum.
33
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
34
Variation in temperature between 20 and 37° C did not 
significantly affect the absorbance readings {i.e. <2$).
Both continuous variation and molar ratio studies ind­
icated that the composition of the complex was 2sl reagents
gold. The experimental value for the dissociation constant
-14of the complex was l.*f x 10
The method was found to be very reproducible.
The effect of various cations and anions commonly found 
in biological systems was studied. Only Fe(III) and Cu(II) 
were found to interfere. One mg of Fe(III) could be toler­
ated when masked with F~. Cu(II) in amounts up to 15 pg 
could be tolerated. Since Cu(II) is normally present in 
plasma at a concentration of about 2 pig/ml, a toleration 
limit of 15 pig is quite acceptable.
In summary, the study with pure HAuCl^.3H20 indicated 
that a stable 2si reagentsgold complex was formed which was 
relatively free from interferences from cations and anions 
commonly found in biological materials. Color development 
was rapid at room temperature. The method gave reproducible 
results and at this point it was felt that it should be 
applicable to the determination of gold in plasma and urine.
Next, preliminary studies were undertaken to determine 
gold in plasma, A suitable digestion technique was develop­
ed employing chloric acid as digestant. The formation of 
gold(III) chloride was carried out employing a method which 
bypasses the usual air-drying step; thus saving a significant 
amount of time.
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Once suitable methods for digestion and formation of 
gold(III) chloride had been found, replicate analyses on 
plasma were carried out at various levels of gold. Good 
recoveries were obtained with a standard deviation of -3$» 
When determining gold in plasma, it was found that the comp- 
lex was stable for about 90 minutes, but for maximum precis­
ion it is recommended that the absorbance be measured 10 
minutes after the addition of DPK.
The digestion procedure was modified slightly for the 
determination of gold in urine and replicate analyses were 
performed. Good recoveries were again obtained with a stand­
ard deviation of <-3$. When analyzing urine samples it was 
found that the absorbance was maximal about 7 minutes after 
the addition of DPK and was stable for another 3-5 minutes 
and then slowly decreased.
This investigation illustrated that DPK may be used for 
the spectrophotometric determination of gold(III) in aqueous 
solution without extracting the complex into an organic 
phase. A specific, simple and relatively rapid method for 
the determination of gold in plasma and urine was developed.
The digestion with chloric acid is rapid and easily 
carried out. All reactions are carried out in the same 
vessel and the only transfer required is in the final dilut­
ion step. DPK and its ethanolic solution are both stable 
indefinitely and the oxime is easily prepared in high yield 
from the commercially available parent ketone. The standard 
solution of HAuCl^.3*^0 was stable for 9 months when kept at
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
room temperature and protected from light.
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CHAPTER IV
SUMMARY
A spectrophotometric method for the determination of 
microgram quantities of gold(III) in aqueous solution with 
di-2-pyridylketoxime was developed. Various analytical 
parameters were studied. A stable 2s1 reagents gold water-
soluble complex is formed having an absorption maximum at
. Ur '*1-33 nm and a molar absorptivity of 1.89 x 10 . The Beer-
Lambert law is obeyed up to 12 ppm.
The method was applied to the determination of gold in 
plasma and urine. It is based on the destruction and remov­
al of interfering substances by chloric acid digestion foll­
owed by formation of gold(III) chloride by aqua regia and 
finally the formation of a water-soluble complex of gold(III) 
with dl-2-pyridylketoxime. The method is simple, reproduc­
ible and relatively rapid.
37
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APPENDIX I
LEAST MEAN SQUARES COMPUTER PROGRAM
The program on the following pages was used to evaluate 
the equations of the lines of best fit for the continuous 
variation and molar ratio studies.
The formulae used are as follows*
SLOPE = - nSxy
(Si)2 - n2x2
Y-INTERCEPT = y
(Si)2 - nS:2
38
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LEAST MEAN SQUARES PROGRAM 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
d e f i n i t i o n  of v a r i a b l e s
R RUN NUMBER IFOR IDENTIFICATION)
N NUMBER OF PAIRS OF Y- AND X-AXIS VARIABLES FOR ONE RUN
Y ! I ) VARIABLE ON Y-AXIS
X ( I ) VARIABLE ON X-AXIS
SLOPE SLOPE OF LEAST MEAN SQUARES (LMS) LINE
YINT Y-INTERCEPT OF LMS LINE
X I NT X-INTERCEPT OF LMS LINE
CC CORRELATION COEFFICIENT
STDERY STANDARD e r r o r  of e s t i m a t e  FOR Y-AXIS v a r i a b l e
STDERX STANDARD ERROR of ESTIMATE FOR X-AXIS VARIABLE
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
LAST DATA CARD is p u n c h e d  a s f o l l o w s  f o r n o r m a l e x i t
COLUMNS 1-6 END999
DOUBLE PRECISION SXiSViSXY tSXXiSYViCiSLOPE .YINT.XINT. STDERY.STDERX 
1 • STDDEY * STDDEX.Y.XiCC.OSQRT.DABS 
DIMENSION Y (60) * X (60)
READ 2.R.N 
FORMAT!A3.13)
IF(N—999) 3.6.3
READ 4, <Y< I ).XI I ).1 = 1 iNI
FORMAT<8(F5.3.F4.0))
CALL LMSIY.X. I.N.SLOPE,YI NT.X I NT.CC.STDERY.STDERX)
PRINT 5.R.SLOPE.YINT.XINT.CC.STDERY.STDERX
FORMAT! 1H .4HRUN .A3/1H .6HSL0PE=.D 15•8.5X.5HYI NT=.D 15•6.5X.5HXI NT 
1=.D15.8/1H .3HCC=.D15.8/1H .7HSTDERY=.D 15.8«1 OX.7HSTDERX = .D 15.8//) 
GO TO 1 
CALL EXIT 
END
LEAST MEAN SQUARES SUBROUTINE ***** BCD ***** DOUBLE PRECISION 
SUBROUT INE LMS(Y .X , I,N ,SLOPE.YI NT.X I NT.CC.STDERY.STDERX)
DOUBLE PRECISION SX,SY.SXY.SXX.SYY.C .SLOPE.YI NT.X INT«STDERY.STpERX 
1.STDDEY « STDDEX,Y ,X .CC.DSQRT.DABS 
DIMENSION Y (60).X (60)
SX = 0 .
SY = D.
SXY=0.
S X X = 0 .
5 Y Y - 0 .
DO 900 I=1.N 
SX=SX+X(I) 
s y =s y +y i I)
SXY = SXY + XI 1 )*Y( I )
SXX=SXX+X<I)*X!I)
SYY = SYY+Y! I )*Y < I )
CONTINUE 
C = N
SLOPE=ISX*SY-C*SXY)/ISX*SX-C*SXX)
YI NT = (SX*SXY-SXX*SY >/!SX*SX-C*SXX) 
x i n t =-y i n t /s l q p e
s t d o e v . d s o p t ISYV/C-(SY/CI *(S Y / C ) )
STDDEX=DSQRT(SXX/C-ISX/C)*(SX/C))
CC=!!SXY/C)-<SX/C)*!SY/C))/!STDDEY*STDDEX)
IF(DABS<CC)-1.DO) 901.902.902 
STDERY=STDDEY*DSQRT!1.DO—CC*CC)
STDERX = STDDEX*OSQRT< 1.00-CC*CC>
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GO TO 904
902 STDERY* 0•
STDERX=0.
PRINT 903
903 FORMAT <1H *13HA6S(CC) *GE*1>
904 RETURN 
END
**************** ******•**■*■■#■* ************ **#•******■#•** *■*■•**■**■*■**** **■*•* 
INPUT DATA FOR LMS PROGRAM
W 0 6 6
0120 030 0239 060 0448 115 0661 170 0963 250 1161 300
OUTPUT FOR LMS PROGRAM
RUN W06
SLOPE= 0*384 129750—02 YINT= 0.64666421D-02 X 1NT=-0.16834526D 01
CC= 0.99998295D 00
STDERY* 0.217708470-02 STDERX* 0.56674798D 00
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APPENDIX II
STANDARD DEVIATION COMPUTER PROGRAM
The program on the following page was used to evaluate 
the mean, standard deviation and % relative standard deviat­
ion for the reproducibility studies.
The formula used for the standard deviation is as 
follows:
STANDARD DEVIATION =
n
(x - x ) 
i=l_______
n - 1
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PCRSD PER CENT RELATIVE STANDARD DEVIATION 
* * * * * * * * * * * * * * * * *  * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * *  * * * * * *  * * * * * * * * * *
LAST DATA CARD IS PUNCHED AS FOLLOWS FOR NORMAL EXIT 
COLUMNS 1-6 END999
R
N
X ( I )
AVG
SD
STANDARD D E V I A T I O N  PROGRAM 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  * * * * * * * *  * * * * * * * *
D E F I N I T I O N  OF VARIABLES
RUN NUMBER (FOR IDENTIFICATION) 
NUMBER OF MEASURED VALUES 
MEASURED VALUE 
MEAN VALUE 
STANDARD DEVIATION
DIMENSION X (60)
1 READ 2 » R » N
2 FORMAT (A3. 13)
IF (N-999) 3*5*3
3 READ 4. < X ( 1 ) * 1 = 1 * N >
4 FORMAT (14F5.3)
PRINT 100.R
100 FORMAT ( 1 HU.A3)
CALL STDDEV < X * I ,N)
GO TO 1
5 CALL EXIT 
END
C STANDARD DEVIATION SUBROUTINE *****
SUBROUTINE STDDEV(X ,I«N >
DIMENSION X (60)
SUM = 0•
DO 800 I = 1 *N 
SUM=SUM+X(I)
800 CONTINUE 
XN-N
AVG=SUM/XN
DEV=0.
DO 801 I=1,N
DEV = DEV+(AVG-X< I ) ) **2
801 CONTINUE
SD= SORT(DEV/(XN-1.))
PCRSD=(SD/AVG)*10U.
PRINT 802.AVG.5D.PCRSD
802 FORMAT (1H .5LMEAN=.E 15.8.5X .3HSD=»E 15•8.5X.21HPER CENT RELATIVE S 
1 D* .E 15. 8 )
RETURN
END
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
INPUT DATA FOR STANDARD DEVIATION PROGRAM
3 0 10
0120 0121 0120 0121 0119 0120 0121 0120 0120 0119
OUTPUT FOR STANDARD DEVIATION PROGRAM
30
MEAN= 0.12009990E 00 SD= 0.73785490E-03 PER CENT RELATIVE SD= 0.61436740^ 00 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
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